“国17条”政策下临床药学的发展战略  

Development strategy of clinical pharmacy under the policy of “State 17 articles”

作　　者：续畅[1] 王晓东[1] 董远[1] 钟萌[1] 黄凤[2] 赵奎君[1] 

机构地区：[1]首都医科大学附属北京友谊医院中药剂科,北京100050 [2]首都医科大学附属北京中医医院针灸科,北京100010

出　　处：《中国现代医生》2017年第14期127-130,共4页China Modern Doctor

基　　金：国家自然科学基金青年科学基金项目(81503580)

摘　　要：2017年国务院办公厅发布了《国务院办公厅关于进一步改革完善药品生产流通使用政策的若干意见》,业内简称"国17条"。该文件既是临床药学及医院药学的发展机遇,同时也是严峻的挑战。为此,本文主要总结多位业内领导、专家对该文件的认识及理解,并对其进行了深层次的解读,以期为各相关单位的药学部门提供改革思路及发展战略。In 2017, the General Office of the State Council promulgated the ＂Opinions of the General Office of the State Council on Further Reforming and Perfecting the Policy on the Use of Drug Production and Circulation＂, referred as ＂State 17 articles＂ in the industry. The document is not only a development opportunity, but also a serious challenge for clinical pharmacy and hospital pharmacy. Based on this, the author summed up the understanding of the document from a number of industry leaders and experts, and understood its deep interpretation, to provide reform ideas and de- velopment strategies for relevant units of the pharmaceutical sector.

关 键 词：国17条 临床药学 医院药学 解读 改革方向 发展战略 

分 类 号：R95[医药卫生—药学]